Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
Strik, Anne S, van de Vrie, Wim, Bloemsaat-Minekus, Joanne P J, Nurmohamed, Michael, Bossuyt, Peter J J, Bodelier, Alexander, Rispens, Theo, van Megen, Yvonne J B, D'Haens, Geert R
Published in The lancet. Gastroenterology & hepatology (01.06.2018)
Published in The lancet. Gastroenterology & hepatology (01.06.2018)
Get more information
Journal Article
Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan
Meijs, Jessica, Voskuyl, Alexandre E, Bloemsaat-Minekus, Joanne P J, Vonk, Madelon C
Published in Rheumatology (Oxford, England) (01.02.2015)
Published in Rheumatology (Oxford, England) (01.02.2015)
Get full text
Journal Article
Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
Pierik, Marieke J, van der Meulen, Andrea E, Van der Linde, Klaas, Lutgens, Maurice, Kuijvenhoven, Johan P, Akol, Halil, Klompmaker, Ids J, Sikkens, Michelle S G, van Megen, Yvonne J B, Stoop, Corinne M, Bloemsaat-Minekus, Joanne P J, Dijkstra, Gerard
Published in Crohn's & colitis 360 (01.07.2022)
Published in Crohn's & colitis 360 (01.07.2022)
Get full text
Journal Article